Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q3 EPS of ($1.28), $0.07 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $399.6 thousand.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.